Dallas, Texas 02/25/2014 (FINANCIALSTRENDS) – BG Medicine, Inc.(NASDAQ:BGMD) is the Waltham based life sciences company which offers a lot of focus for the development as well as discovery of diagnostic needs. The niche that this medical provider handles is the cardio vascular diagnostics and looks to offer special therapies especially for those regions where no treatment has been successful.
BG Medicine, Inc.(NASDAQ:BGMD) has focused or built a platform developed on blood-based tests. The lead product which BG Medicine has developed is the Cardio SCORE. This means that there are several multi-analyte biomarker-based blood tests. All of these tests are considered to be vulnerable plaque.
BG Medicine, Inc.(NASDAQ:BGMD) latest results of a clinical research study which endorses its automated VIDAS Galectin -3 assay. This product was developed by one of BGMDs lead partners called as Biomerieux which specializes in virto diagnostic.
BG Medicine, Inc.(NASDAQ:BGMD) has a supply agreement with companies such as Health Diagnostic Laboratory. These are already used in the US along with Galectin-3 tests with a wide range of regional as well as national laboratory testing infrastructure.
BG Medicine, Inc.(NASDAQ:BGMD) has also moved into manufacturing its drugs with the help of over four diagnostic instrument manufacturers. These are used to develop automated versions and instruments for the test.
BG Medicine, Inc.(NASDAQ:BGMD) currently holds a market cap of $38.53 million. For this pharmaceutical company the infra day trading range has been between $1.36 and $1.40. The company has also traded on the 52 week between $2.28 high and $0.55 low. As of the opening of the trading, the company has reported $1.38 stock price. The average stock price for the company has been $1.29. Besides, the EPS of the company was reported at -0.66. The shares for the company are at 27.92 million. The volume trade for the stock was 32,023, while the average trading volume was 1.33 million.